Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2003

View Archived Issues

Phase I interim safety data reported for Reolysin in malignant glioma

Results reported for NBI-3001 in glioblastoma

Cytogen regains rights to ex vivo prostate cancer immunotherapy

Velcade enters phase II trial in colorectal cancer

MoliChem reacquires rights to Moli-1901

AEterna acquires Zentaris from Degussa

Zindaclin receives further E.U. approvals

NexMed completes dosing in two-year rat carcinogenicity study

Crucell regains rights to anti-CD46 antibody

IND filed for EOS-200-4

Topamax sNDA submitted for migraine prevention

Xenova advances two new programs into preclinical research

Restasis receives FDA approval

Amylin to acquire rights to Restoragen's GLP-1 program

Inspra meets primary endpoints in EPHESUS trial

COX-2-specific inhibitor LAS-34475 compares favorably to naproxen in osteoarthritis

HDAC inhibitor MS-275 active against pediatric solid tumors in vitro and in vivo

Third phase III MorphiDex trial fails to meet endpoints

Pharmacokinetic, toxicity and efficacy data for LEraf-AON in animals

Highly selective CB2 receptor ligand emerges from SAR studies at U.S. universities

New central muscle relaxant/antiinflammatory/analgesic advanced to clinical evaluation at GSK

Novel caspase inhibitors and their use reported by Vertex

Anticonvulsant compounds in early development at UCB

Ono patent covers new endothelial differentiation gene-1 (EDG1) agonists

New JAK3 inhibitors identified at AstraZeneca

Nonredox antiobesity cobalt porphyrin complexes discovered at MitoKor

Modified antisense oligonucleotides targeting ICAM-1 and VCAM-1 show potential in IBD

Galderma describes new series of vitamin D analogues for skin disorders

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026